Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

CELGENE CORPORATION

(CELG)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/20/2019 05/21/2019 05/22/2019 05/23/2019 05/24/2019 Date
94.83(c) 96.25(c) 96.36(c) 95.63(c) 95.24(c) Last
4 497 032 2 892 576 3 014 310 4 869 969 3 446 762 Volume
-0.62% +1.50% +0.11% -0.76% -0.41% Change
More quotes
Financials (USD)
Sales 2019 17 137 M
EBIT 2019 9 896 M
Net income 2019 6 372 M
Debt 2019 8 583 M
Yield 2019 -
Sales 2020 19 232 M
EBIT 2020 11 286 M
Net income 2020 7 430 M
Debt 2020 3 323 M
Yield 2020 -
P/E ratio 2019 11,21
P/E ratio 2020 9,53
EV / Sales2019 4,42x
EV / Sales2020 3,67x
Capitalization 67 169 M
More Financials
Company
Celgene Corporation specializes in the design, development, and sale of products for treating cancer and immune system disorders. Net sales break down by product family as follows: - therapeutic products (99.8%); - other (0.2%): cellular therapy products and biological materials for implants, for... 
Sector
Pharmaceuticals
Calendar
06/01 | 02:15pmPresentation
More about the company
Surperformance© ratings of Celgene Corporation
Trading Rating : Investor Rating :
More Ratings
Latest news on CELGENE CORPORATION
05/21CELGENE : and the Multiple Sclerosis Association of America Team Up to Launch MS..
BU
05/17CELGENE : Receives European Commission Approvals for REVLIMID and IMNOVID based ..
AQ
05/16CELGENE : Says EC Approves two Triplet Regimens for Multiple Myeloma
DJ
05/16CELGENE : Receives European Commission Approvals for REVLIMID® (lenalidomide) an..
BU
05/15CELGENE : to Highlight New and Updated Hematology and Oncology Clinical Data at ..
BU
05/13CELGENE : Says FDA Grants Breakthrough Designation to Pomalyst
DJ
05/13CELGENE CORPORATION : Announces POMALYST® Granted Breakthrough Therapy Designati..
BU
05/13ENZO BIOCHEM INC. : Announces Issuance of United States Patent for Treatment of ..
AQ
05/10LYFEBULB AND CELGENE ANNOUNCE FINALI : An Innovation Challenge"
PR
05/10PATRICK THOMAS : Biotech Industry Woos Talent With Top Pay -- WSJ
DJ
More news
Analyst Recommendations on CELGENE CORPORATION
More recommendations
Stock Trading Strategies
CELGENE CORPORATION - 03/28
In an accumulation phase
BUY
More Stock Trading Analysis
Sector news : Pharmaceuticals - NEC
05/24NOVARTIS : At $2 Million, New Novartis Drug Is Priciest Ever
DJ
05/24NOVARTIS : Correction to Novartis Article
DJ
05/24NOVARTIS : FDA Approves Novartis' Piqray for Breast Cancer
DJ
05/24NOVARTIS' : Zolgensma Approved for Sale in U.S. to Treat SMA in Infants at $2.12..
DJ
05/24SAMSUNG ELECTRONICS : South Korea orders further arrests at Samsung Electronics ..
RE
More sector news : Pharmaceuticals - NEC
Chart CELGENE CORPORATION
Duration : Period :
Celgene Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 21
Average target price 97,0 $
Spread / Average Target 1,8%
EPS Revisions
Managers
NameTitle
Mark J. Alles Chairman, President, CEO & COO
David V. Elkins Chief Financial Officer & Executive Vice President
Joseph S. Camardo Senior Vice President-Global Medical Affairs
Jay T. Backstrom Chief Medical Officer
Rupert J. Vessey President-Research & Early Development
Sector and Competitors
1st jan.Capitalization (M$)
CELGENE CORPORATION49.21%67 169
JOHNSON & JOHNSON8.32%371 150
PFIZER-3.96%233 072
ROCHE HOLDING LTD.10.72%230 177
NOVARTIS14.01%212 054
MERCK AND COMPANY6.03%208 598